United Kingdom · Question · Written question
UIN 4364
Trastuzumab Deruxtecan
Introduced
29 November 2023
Last action
5 December 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
5 December 2023
Summary
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the National Institute for Health and Care Excellence on when it plans to conclude its appraisal of trastuzumab deruxtecan for treating HER2-low metastat
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
29 November 2023
Written question
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the National Institute for Health and Care Excellence on when it plans to conclude its appraisal of trastuzumab deruxtecan for treating HER2-low metastat
Source: Commons
5 December 2023
Answer
We have had no such discussions. The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on trastuzumab deruxtecan for HER2-low metastatic or unresectable breast cancer after chemothera...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-11-29/4364
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1673991
- uk · wq-1673991 · source updated 5 December 2023